NCT02416102 is a Phase 4 clinical trial of Losartan 50 mg in COPD, sponsored by University of Miami.

Who is sponsoring NCT02416102?

NCT02416102 is sponsored by University of Miami.

What drugs are being tested in NCT02416102?

Interventions in NCT02416102: Losartan 50 mg, Losartan 100 mg.

What condition does NCT02416102 study?

NCT02416102 studies COPD, Chronic Bronchitis.

Is NCT02416102 still recruiting?

NCT02416102 is currently terminated. Last updated 20 August 2020.

Are results published for NCT02416102?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-08-20 · How we verify

NCT02416102

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis

Terminated Phase 4 Results posted Last updated 20 August 2020

What this trial tests

Phase 4 trial testing Losartan 50 mg in COPD in 31 participants. Terminated before completion.

Timeline

31 March 2016

Primary endpoint
3 April 2017

3 April 2017

Quick facts

Lead sponsor	University of Miami
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	basic science
Enrollment	31
Start date	31 March 2016
Primary completion	3 April 2017
Estimated completion	3 April 2017
Sites	1 location across United States

Drugs / interventions tested

Losartan 50 mg — full drug profile →
Losartan 100 mg — full drug profile →

Conditions studied

COPD — all drugs for COPD →
Chronic Bronchitis — all drugs for Chronic Bronchitis →

Sponsor

University of Miami

Who can join

Adults 35 to 75, any sex, with COPD or Chronic Bronchitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change in IL-8 Concentrations Secondary · Baseline, 8 weeks

Interleukin (IL)-8 concentrations were analyzed from samples on nasal lavage

Group	Value	95% CI
Healthy Non-smokers	2867	± 1685
Smokers Without COPD	4676	± 1948

Percent Change in TGF-ß mRNA Expression Secondary · Baseline, 8 weeks

Transforming Growth Factor (TGF)-ß messenger ribonucleic acid (mRNA) expression were analyzed from nasal cells samples.

Group	Value	95% CI
Healthy Non-smokers	-51	± 31
Smokers Without COPD	-23	± 70

Sponsor's own description

The purpose of this study is to evaluate the effect of Losartan on cigarette smoke-induced lung injury in smokers and ex-smokers with and without chronic obstructive pulmonary disease (COPD).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging pharmaceutical therapies for COPD.
Lakshmi SP, Reddy AT, Reddy RC. · · 2017 · cited 35× · PMID 28790817 · DOI 10.2147/copd.s121416
Losartan reduces cigarette smoke-induced airway inflammation and mucus hypersecretion.
Kim MD, Baumlin N, Dennis JS, Yoshida M, et al · · 2021 · cited 16× · PMID 33532463 · DOI 10.1183/23120541.00394-2020

Verify or expand the search:

Other trials of Losartan 50 mg

Trials testing the same drug.

NCT07099859 — Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Unde · Phase 4 · recruiting
NCT00090259 — Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patient · Phase 3 · completed

Other recruiting trials for COPD

Currently open trials in the same condition.

NCT07344649 — Turkish Validation of the Nijmegen Questionnaire in COPD · recruiting
NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
NCT07460154 — Structured Review: To Optimise Management and Prevent Harm in COPD · NA · recruiting
NCT07462221 — Effect of Telenursing on Oral Health · NA · recruiting
NCT07051707 — Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD · NA · recruiting

Other University of Miami trials

Trials by the same sponsor.

NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI) · NA · not yet recruiting
NCT06077071 — MRIdian "RADAR" Trial · NA · not yet recruiting
NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project · Phase 3 · not yet recruiting
NCT07322289 — Antibiotic-coated Braided Suture Study · NA · not yet recruiting
NCT07469592 — eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02416102 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Miami
Last refreshed: 20 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02416102.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing